‹ ›
MYP_149262
← PREVIOUS NEXT → BACK
Basic Information
sHR2-3
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
56 amino acids
C277H446N74O94
Standard
Sequence
LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE
Physicochemical Analysis
6316.94 Da
4.59
-5.13
-5.41
-0.0917
-0.55
0.70
-0.06
26.35
107.86
0.0536
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
2772.34
-28.00
91.0
90.0
220.0
445.0
5.0
63.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0312806 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome-related coronavirus [Virus]
Virus-derived peptide
694009;0
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
SARS coronavirus (Fusion); Vero
50 μM
EC50
PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
RECORD: Rec_0339846 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | 118 cells
50 μM
EC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. | DOI:10.1073/pnas.0400576101 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
RECORD: Rec_0376996 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
SARS-CoV
PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
FIRST PREV 1 2
Showing 3 records on this page · Page 2 of 2